An 'Iterative Process'

Sidebar: The AIDS Research Evaluators The 100-plus members of a newly constituted National Institutes of Health task force have begun their daunting task: a comprehensive reevaluation of NIH's entire $1.4 billion AIDS portfolio, including both intramural and extramural research. Compounding the challenge for the scientists and AIDS activists who make up the task force is a withering schedule. They will have to produce a report due in January 1996, to aid in planning the 1998 Office of AIDS Rese

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

The 100-plus members of a newly constituted National Institutes of Health task force have begun their daunting task: a comprehensive reevaluation of NIH's entire $1.4 billion AIDS portfolio, including both intramural and extramural research. Compounding the challenge for the scientists and AIDS activists who make up the task force is a withering schedule. They will have to produce a report due in January 1996, to aid in planning the 1998 Office of AIDS Research (OAR) budget.

Some panel members wonder if they can pull it off. They worry about getting the information they need quickly from 24 NIH institutes and centers that are not always in sync. More important to many task force members, a number of whom have sat on AIDS panels before, is whether their efforts will make a difference this time--whether their recommendations will become the government's AIDS agenda.

But interviews with several panel members reveal widespread ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Billy Goodman

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide